Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Renal Cell
  • Interferon-alpha
  • Kidney Neoplasms
  • Sirolimus

abstract

  • As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov number, NCT00065468 [ClinicalTrials.gov].).

publication date

  • May 31, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa066838

PubMed ID

  • 17538086

Additional Document Info

start page

  • 2271

end page

  • 81

volume

  • 356

number

  • 22